Return to home page
Searching: Muskingum library catalog
Some OPAL libraries remain closed or are operating at reduced service levels. Materials from those libraries may not be requestable; requested items may take longer to arrive. Note that pickup procedures may differ between libraries. Please contact your library for new procedures, specific requests, or other assistance.
  Previous Record Previous Item Next Item Next Record
  Reviews, Summaries, etc...
EBOOK
Title SUBSTANCE AND NON SUBSTANCE RELATED ADDICTION DISORDERS : diagnosis and treatment (1).
Imprint [Place of publication not identified] : BENTHAM Science PUBLISHER, 2017.

Subject Substance abuse -- Diagnosis.
Substance abuse -- Treatment.
Compulsive behavior.
Alt Name Bhatia, Subhash C.,
Petty, Frederick,
Gabel, Teri,
Description 1 online resource
Bibliography Note Includes bibliographical references and index.
Contents FOREWORD ; PREFACE ; List of Contributors ; Section I: General Topics ; Neurobiology and Psycho-Social Basis for Addiction and Related Disorders ; KEY LEARNING POINTS; NEUROBIOLOGY OF ADDICTION AND REWARD PATHWAYS; PSYCHOSOCIAL FACTORS; ADVERSE CHILDHOOD EXPERIENCES (ACE); CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Urine Drug Screening (UDS) in the Management of Substance Use Disorders ; KEY LEARNING POINTS; CLINICAL VIGNETTE; DIAGNOSTIC CONSIDERATION; REASONS FOR OBTAINING AN UDS; URINE DRUG SCREENS; Types of Urine Drug Tests; Urine Drug Test as a Follow-up Tool.
Urine Sample CollectionChain of Custody; Medication Interfering with UDS; SPECIAL CONSIDERATIONS; Opiate/Opioid Metabolism; Benzodiazepines; Untested Substances; Altered Pharmacokinetic and Pharmacodynamic Parameters; SUMMARY; PATIENT INFORMATION SHEET -- URINE DRUG SCREENS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Genetics of Addiction ; KEY LEARNING POINTS; GENETICS OF ADDICTION; SUMMARY; PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Dual Diagnosis ; KEY LEARNING POINTS; CLINICAL VIGNETTE; BACKGROUND; DIAGNOSTIC CONSIDERATIONS.
TREATMENT CONSIDERATIONSTREATMENT OUTCOMES; SUMMARY; DUAL DIAGNOSIS -- PATIENT INFORMATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Pharmacologic Treatment for Psychiatric Disorders Associated with Substance Use Disorders: An Overview ; KEY LEARNING POINTS; INTRODUCTION; Benzodiazepines (Table 1); Antidepressants; Serotonin Syndrome; Syndrome Presentation; Treatment; SSRI Withdrawal Phenomenon; Atypical/Typical Antipsychotics; Dosing; Monitoring; Additional Monitoring Recommended; Other Side Effects; Extrapyramidal Side Effects (EPSE); Treatment of Early -- EPSE.
Dystonias and PseudoparkinsonismAkathisia; Treatment of Tardive Dyskinesia; Neuroleptic Malignancy Syndrome (NMS); Mood Stabilizers; Anticonvulsants; Management of Insomnia; SUMMARY; PATIENT INFORMATION -- MEDICATIONS FOR SUBSTANCE USE DISORDERS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Motivational Interviewing ; KEY LEARNING POINTS; BACKGROUND; PROCESS; MOTIVATION ENHANCEMENT; THE STAGES OF CHANGE; SUMMARY; MOTIVATIONAL INTERVIEW-PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Section II: Substance-Related Addiction Disorders (Alphabetical).
Alcohol Use Disorders KEY POINTS; CLINICAL VIGNETTE; INTRODUCTION; Epidemiology; Etiology; Diagnosis; Non-Pharmacologic Interventions; Pathophysiology of Alcohol Use Disorders (AUD); PHARMACOTHERAPY FOR ALCOHOL USE DISORDERS (AUD); Management of Outpatient Alcohol Withdrawal; FDA Approved Medications for Alcohol Use Disorder [26]; Disulfiram (Antabuse®) [19, 21, 27]; Naltrexone (Revia® (PO), Vivitrol® (IM)); Acamprosate (Campral®) [21, 28, 30]; Combination Therapy; Non-FDA Approved Pharmacotherapies for AD; SUMMARY; CLINICAL VIGNETTE RESOLUTION; PROVIDER RESOURCES.
ISBN 1681083434 (electronic bk.)
9781681083438 (electronic bk.)
OCLC # 984523853
Additional Format Print version: Bhatia, Subhash C. Substance and Non Substance Related Addiction Disorders: Diagnosis and Treatment. Sharjah : Bentham Science Publishers, ©2017 9781681083445


If you experience difficulty accessing or navigating this content, please contact the OPAL Support Team